loading page

COVID-19 vaccine (mRNA BNT162b2) and COVID-19 Infection-Induced Thrombotic Thrombocytopenic Purpura in Adolescents
  • +3
  • Luna Vorster,
  • Susan Kirk,
  • Eyal Muscal,
  • Jenny Despotovic,
  • Clay Cohen,
  • Sarah Sartain
Luna Vorster
Baylor College of Medicine

Corresponding Author:[email protected]

Author Profile
Susan Kirk
Baylor College of Medicine Department of Pediatrics
Author Profile
Eyal Muscal
Baylor College of Medicine/Texas Children's Hospital
Author Profile
Jenny Despotovic
Texas Children's Hospital
Author Profile
Clay Cohen
Baylor College of Medicine
Author Profile
Sarah Sartain
Baylor College of Medicine
Author Profile


The mRNA COVID-19 vaccine and COVID-19 infection caused by the SARS-CoV-2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID-19 vaccination or infection in pediatric or adolescent patients. We describe 4 adolescents presenting with TTP (both de novo and relapsed disease) following administration of the Pfizer COVID-19 vaccine or after COVID-19 infection. Our observations demonstrate that the Pfizer-BioNTech mRNA vaccine and COVID-19 infection can act as triggers for the development/relapse of both congenital and acquired TTP.
23 Nov 2021Submitted to Pediatric Blood & Cancer
23 Nov 2021Submission Checks Completed
23 Nov 2021Assigned to Editor
24 Nov 2021Reviewer(s) Assigned
16 Dec 2021Review(s) Completed, Editorial Evaluation Pending
16 Dec 2021Editorial Decision: Revise Major
08 Feb 20221st Revision Received
08 Feb 2022Submission Checks Completed
08 Feb 2022Assigned to Editor
09 Feb 2022Reviewer(s) Assigned
04 Mar 2022Review(s) Completed, Editorial Evaluation Pending
04 Mar 2022Editorial Decision: Accept
Jun 2022Published in Pediatric Blood & Cancer volume 69 issue 6. 10.1002/pbc.29681